جستجوی استاد راهنمای دانشگاهی

Mohamed Benderdourمشاهده پروفایل

استاد

• Biochemistry of lipid peroxidation aldehydes
• Joint diseases
• Cellular metabolism alteration
• +۷ مورد دیگر

Mohamed Benderdour is a Full Professor in the Department of Surgery at the University of Montreal and a Regular researcher at the Research Center of the Sacré-Coeur Hospital of Montreal, where he contributes to the Trauma – acute care research axis. His academic career spans over two decades with significant contributions to biochemical research related to joint diseases. Dr. Benderdour's research primarily focuses on the biochemistry of lipid peroxidation aldehydes and their implications in joint diseases, particularly osteoarthritis. His work investigates how aldehydes alter cellular metabolism and cause post-translational modifications of proteins, with specific attention to cell signaling mechanisms involving protein kinases and transcription factors. He has extensively studied 4-hydroxynonenal and its role in osteoarthritis pathogenesis, exploring mechanisms of gene regulation and promoter analysis in joint tissue pathology. Analysis of Dr. Benderdour's publication history reveals an evolution from fundamental biochemical mechanisms to increasingly translational research. His recent work shows strong emphasis on RNA modifications in osteoarthritis (epitranscriptomics), nanotechnology approaches for therapeutic delivery (particularly chitosan-based nanovectors for siRNA), and the pathophysiology of immunoporosis. His publications demonstrate a progression toward developing therapeutic applications from basic science discoveries. Dr. Benderdour maintains a productive research career with publications spanning molecular biology, biochemistry, rheumatology, and nanotechnology. His work bridges basic science with potential clinical applications in orthopedics and joint disease treatment, reflecting a commitment to advancing both scientific understanding and potential therapeutic interventions for osteoarthritis and related conditions.

Pavel Sumazinمشاهده پروفایل

استاد

• Computational Biology
• Genomics
• Molecular Profiling
• +۳ مورد دیگر

Pavel Sumazin is a Professor in the Department of Pediatrics at Baylor College of Medicine. He holds additional affiliations with the Dan L Duncan Comprehensive Cancer Center and the Quantitative and Computational Biosciences program at Baylor. His research focuses on computational and molecular analyses of cancer genomics, particularly in pediatric tumors. Major areas include non-coding RNA regulation, gene expression networks, and functional interpretation of genomic variants in cis and trans contexts. His work bridges computational biology with experimental validation to identify cancer driver genes and therapeutic targets. Recent publications highlight his expertise in lncRNA-target interactions, radiosensitivity prediction in pancreatic cancer, and innovative CAR T-cell therapies for solid tumors. His laboratory develops computational models for bulk RNA-Seq deconvolution and investigates metabolic vulnerabilities in neuroblastoma and leukemia. Prof. Sumazin's work has contributed to understanding tumor heterogeneity in hepatoblastoma, mechanisms of chemotherapy resistance in pediatric AML, and safety concerns in CRISPR/Cas9 gene therapy. His methodologies integrate machine learning with experimental validation for clinical applications.

Ashish Misraمشاهده پروفایل

استادیار

• Genomics
• Epitranscriptomics
• Cancer RNA Biology
• +۸ مورد دیگر

Ashish Misra is an Assistant Professor in the Department of BioTechnology at the Indian Institute of Technology Hyderabad . His research spans interdisciplinary fields including genomics, epitranscriptomics, and molecular virology, with applications in cancer biology, drug discovery, and nanoscience. Education : Ph.D. from Indian Institute of Science (IISc), Bengaluru Office Address : Room B-312, Academic Block B, IIT Hyderabad, Kandi-502284, Sangareddy, Telangana, India Contact : Office Phone: (040) 2301 - 6158

Ajit Divakaruniمشاهده پروفایل

استادیار

• Metabolism
• Mitochondrial Biology
• Bioenergetics
• +۴ مورد دیگر

Ajit Divakaruni serves as Assistant Professor at the University of California, Los Angeles, leading a research laboratory dedicated to mitochondrial metabolism and cellular bioenergetics. His work integrates metabolomics, 13C isotope tracing , and live-cell imaging to investigate how substrate preferences regulate cell function across physiological contexts. His academic journey includes: B.S. (summa cum laude) in Biochemistry, Molecular Biology, and Applied Mathematics from University of Arizona (2006) Ph.D. in Biochemistry from University of Cambridge under Dr. Martin Brand (2011), funded by British Marshall Scholarship Postdoctoral training in Pharmacology at UC San Diego (2011-2017) with industry fellowship from Seahorse Bioscience Divakaruni's research centers on mitochondrial regulation of cellular fate, with emphasis on inflammatory cytokine reprogramming , brain aging interventions , and bioenergetic methodology development . His lab explores how metabolic shifts between sugar, amino acid, and fatty acid oxidation impact immunometabolism and neurodegeneration, employing advanced techniques to identify therapeutic targets for Alzheimer's disease and metabolic disorders. Recent publications reveal dominant themes in macrophage metabolic reprogramming , mitochondrial enzymology , and neurodegenerative disease mechanisms , demonstrating that inflammatory activation occurs without oxidative phosphorylation inhibition and that Coenzyme A enhances alternative macrophage functions through MyD88 signaling. Scientific recognition includes: British Marshall Scholarship NSF Graduate Research Fellowship Divakaruni mentors four graduate students and one postdoc in grant-funded projects spanning atherosclerosis, Alzheimer's models, and mitochondrial biosynthesis. His laboratory maintains industry partnerships with Agilent Technologies (formerly Seahorse Bioscience) for method development in bioenergetic analysis. Housed in UCLA's Center for Health Sciences, the Divakaruni Lab operates as a multidisciplinary hub for metabolomics and live-cell imaging, collaborating with clinicians to translate mitochondrial discoveries into therapeutic strategies for aging-related diseases.

Chengfeng Yangمشاهده پروفایل

استاد

• RNA dysfunction in carcinogenesis
• Cancer therapy resistance
• Non-coding RNAs
• +۵ مورد دیگر

Dr. Chengfeng Yang is a Professor in the Department of Pathology at the Renaissance School of Medicine, Stony Brook University. His research program focuses on Oncogenic Drivers and Mechanisms of Carcinogenesis, with particular emphasis on RNA dysfunction in cancer development and resistance to therapies. Dr. Yang received his medical degree from Tongji Medical University, completed his PhD at National University of Singapore, and conducted postdoctoral training at New York University and University of Pennsylvania. This diverse educational background has equipped him with expertise spanning medicine, molecular biology, and toxicology. His laboratory investigates the role and mechanism of RNA abnormal expression and post-transcriptional modifications in cancer initiation (carcinogenesis), progression (metastasis), and therapeutic resistance. The research is grounded in the recognition that human genome is pervasively transcribed, with a large portion transcribed as non-coding RNAs, especially long non-coding RNAs (lncRNAs). His work demonstrates how environmental carcinogens, particularly metals like hexavalent chromium and arsenic, dysregulate RNA molecules leading to cancer stem cell-like properties and tumorigenesis. Analysis of Dr. Yang's recent publication record reveals consistent productivity with expanding interdisciplinary connections, particularly between RNA biology, environmental toxicology, and microbiome research. His work bridges molecular biology, toxicology, and oncology, with significant focus on identifying dysfunctional RNA molecules as potential diagnostic markers and therapeutic targets for cancer prevention and treatment. Dr. Yang actively mentors undergraduate and graduate students in his laboratory, providing research opportunities to study the mechanisms of carcinogenesis. His laboratory serves as a hub for interdisciplinary cancer research at Stony Brook University, collaborating with researchers across multiple departments and institutions.

Gilbert Rahmeمشاهده پروفایل

استادیار

• Cancer epigenetics
• Brain tumor epigenetics
• Gliomas
• +۷ مورد دیگر

Gilbert Rahme is an Assistant Professor in the Department of Pharmacological Sciences at Stony Brook University's Renaissance School of Medicine and the Cancer Center. He leads the Rahme Lab, which focuses on cancer epigenetics with particular emphasis on brain tumors called gliomas. His research is generously supported by the NIH/NCI, the Renaissance School of Medicine, and the Stony Brook Cancer Center. Dr. Rahme's research centers on how epigenetic reprogramming drives tumorigenesis and tumor progression, particularly in gliomas. His lab leverages mouse models, human tumor tissues, and computational analyses to discover epigenetic lesions, computationally infer their driver potential, and functionally demonstrate their role in tumorigenesis using in vitro and in vivo approaches. A major focus is understanding how IDH mutant gliomas exhibit epigenetic reprogramming due to CpG hypermethylation driven by 2HG production from mutant IDH. The Rahme Lab's publications reveal a consistent focus on epigenetic mechanisms in brain cancer, particularly examining DNA methylation, CTCF binding sites, and topologically associated domains (TADs) that define the 3-dimensional shape of the genome. Their research shows how epigenetic lesions can transform oligodendrocyte progenitor cells (OPCs) and drive gliomagenesis. Recent work published in Cell demonstrates how specific epigenetic lesions underlying hypermethylation can transform OPCs, providing critical insights into glioma development. NIH/NCI funding for brain tumor epigenetics research Support from Renaissance School of Medicine and Stony Brook Cancer Center Dr. Rahme actively mentors graduate students and postdocs, with his student Jina Yim recently winning the best poster presentation at the Gloria and Mark Snyder Symposium. The Rahme Lab currently has openings for technicians, graduate students, and postdocs, with particular interest in candidates applying to Molecular and Cellular Pharmacology, Molecular and Cellular Biology, Genetics, and Physiology and Biophysics programs. The Rahme Lab maintains an active presence at major cancer research conferences, including the American Association for Cancer Research special conference on brain cancer, where Dr. Rahme has presented the lab's work on modeling epigenetic drivers of gliomas.

• Chemical Biology
• Cancer Metabolism
• Epigenetics
• +۷ مورد دیگر

Jordan L. Meier, Ph.D. is a Senior Investigator and Head of the Epigenetics and Metabolism Section at the Chemical Biology Laboratory within the Center for Cancer Research at the National Cancer Institute, National Institutes of Health. His research bridges chemical biology, cancer metabolism, and epigenetic regulation, focusing on how metabolic states influence genomic signaling through chromatin modifying enzymes. Dr. Meier's educational background includes: Bachelor's degree in Chemistry from Creighton University (2004) Ph.D. in Chemistry from University of California-San Diego (2009), working under Professor Michael D. Burkart Postdoctoral training as an American Cancer Society fellow at California Institute of Technology with Professor Peter B. Dervan His research interests center on the intersection of metabolism and epigenetics, particularly how metabolic perturbations influence epigenetic signaling. Dr. Meier's laboratory develops chemical approaches to investigate metabolic and epigenetic signaling pathways in cancer, with special focus on acetyl-CoA mediated acetylation mechanisms and oncometabolite-driven cancers. His work aims to discover biological mechanisms underlying oncometabolite-driven cancers, develop new cancer diagnostics, and identify small molecules that inhibit epigenetic modifications through metabolic disruption. Analysis of Dr. Meier's publications reveals a consistent research trajectory exploring the chemical biology of metabolic-epigenetic crosstalk. His work spans from fundamental chemical probe development to cancer-relevant biological applications, with particular emphasis on acetylation-based signaling mechanisms, oncometabolite detection, and chemoproteomic mapping of metabolic enzyme targets. His research has significantly advanced understanding of how metabolites like fumarate and acyl-CoA derivatives regulate epigenetic processes in cancer. Notable recognition includes: American Cancer Society postdoctoral fellowship Dr. Meier actively mentors a diverse research team including postdoctoral fellows and postbaccalaureate researchers. His laboratory has developed innovative chemical tools and approaches that have enabled new avenues for understanding metabolic regulation of epigenetic processes. Current research includes development of the Fumarate Chemoproteomic Reactivity Database to enable community efforts in studying FH-regulated cysteines. The Chemical Biology Laboratory fosters a collaborative environment with active participation in symposia and scientific meetings. Dr. Meier's team engages in both fundamental chemical biology research and translational applications, with a particular focus on developing new approaches for cancer therapy, diagnosis, and chemoprevention based on metabolic-epigenetic connections.

• RNA Biochemistry
• Protein Synthesis
• Translation Mechanisms
• +۵ مورد دیگر

Jinfan Wang is an Assistant Professor and UT Southwestern Endowed Scholar in the Department of Biochemistry at University of Texas Southwestern Medical Center (UTSW). He obtained his B.S. in Biotechnology from the University of Science and Technology Beijing (2010) and a Ph.D. in Biochemistry from Uppsala University (2016), where he studied prokaryotic translation under Dr. Anthony Forster. Supported by the Knut and Alice Wallenberg Foundation, he conducted postdoctoral research at Stanford University (2016–2023) with Dr. Jody Puglisi, developing single-molecule methods to study eukaryotic translation. His lab at UTSW combines quantitative biochemistry, structural biology, and genetics to investigate cytosolic and mitochondrial translation mechanisms. Education B.S., Biotechnology – University of Science and Technology Beijing (2010) Ph.D., Biochemistry – Uppsala University (2016) His research focuses on the dynamic interplay between mRNA structure, ribosome function, and translation regulation in eukaryotes. Using single-molecule fluorescence microscopy, his team established frameworks for understanding start codon recognition, elongation fidelity, and drug-induced translation arrest. Recent work explores mitochondrial translation and its dysregulation in human diseases. Key publications reveal insights into: Eukaryotic translation initiation (Cell 2022, Nature 2019) Ribosome interactions with modified mRNA (Nat Struct Mol Biol 2018) Engineering of translation systems (Nucleic Acids Res 2017) Kinetic bottlenecks in unnatural amino acid incorporation (ACS Chem Biol 2015) Scientific Awards Knut and Alice Wallenberg Foundation Postdoctoral Fellowship UT Southwestern Endowed Scholar Dr. Wang’s lab seeks to bridge fundamental translation mechanisms with therapeutic applications, particularly in diseases linked to mitochondrial dysfunction. They actively recruit graduate students, technicians, and postdocs for interdisciplinary research.

• Immunology
• Molecular Biology
• RNA Biology
• +۵ مورد دیگر

Ana Rebane is a Professor of Molecular Medicine at the University of Tartu's Faculty of Medicine, Institute of Biomedicine and Translational Medicine since October 2019. Previously, she served as a Senior Research Fellow in RNA Biology (2016-2019) and in the Department of General and Molecular Pathology. She has held various research positions at the University of Tartu since 2004, with a visiting scientist position at the Swiss Institute of Allergy and Asthma Research (2010-2013) and a postdoctoral associate at Yale University (2000-2003). Her educational background includes a Doctor's Degree from the University of Tartu (1999) with a thesis on "Mammalian ribosomal protein S3a genes and intron-encoded small nucleolar RNAs U73 ans U82" under Andres Metspalu. She completed her PhD studies from 1995-1998 and earned her degree in Bioorganic Chemistry from Tartu University (1984-1989). Ana Rebane's research focuses on immunology, molecular biology, and RNA biology, particularly in the context of allergy, asthma, and skin conditions. Her work extensively examines the role of microRNAs in immune responses, inflammasome activation, and skin barrier function. She investigates how RNA modifications, particularly in keratinocytes, influence inflammatory responses in conditions like atopic dermatitis and psoriasis. Her research bridges basic molecular mechanisms with clinical applications, exploring therapeutic delivery systems like cell-penetrating peptides for RNA-based treatments. Her publication record shows a strong focus on molecular mechanisms of skin and respiratory inflammation, with recent work emphasizing RNA modifications, inflammasome biology, and innovative delivery systems for nucleic acid therapeutics. Her research demonstrates consistent progression from basic molecular mechanisms to translational applications, particularly in dermatological and respiratory conditions. 2020 Estonian National Science Award (medical sciences) 2019 Academic Leader of Eastern Europe, European Society of Dermatological Research 2015 The Eastern European Dermatology Research Award 2014 Research Fellow from European Society of Dermatological Research 2010 SCIEX stipendium to work at Swiss Institute of Allergy and Asthma Research 2000 Fellowship from NATO-NSF 1997 Fellowship from Finnish Government 1996 Fellowship from Nordic Council of Ministers Ana Rebane serves in significant administrative roles including Member of the University of Tartu Senate (since 2023), President of the Estonian Society of Human Genetics (since 2022), and Board Member of the same society (since 2020). She is an Associated Editor for Frontiers in Allergy (since 2020) and serves on the Reviewer Board of the Journal of Allergy and Clinical Immunology (since 2017). She has been an active member of several professional societies including the European Society of Dermatological Research and the European Academy of Allergy and Clinical Immunology. Her research activities are centered around the Institute of Biomedicine and Translational Medicine at the University of Tartu, where her team investigates molecular mechanisms of immune responses, particularly focusing on RNA biology and its implications for inflammatory skin and respiratory diseases. Her laboratory develops and applies advanced techniques for studying gene regulation, epigenetic modifications, and innovative therapeutic delivery systems.

• Chronic Traumatic Encephalopathy
• Gliomas
• Epigenetics
• +۵ مورد دیگر

Clinical Associate Professor Michael Buckland is affiliated with the University of Sydney and serves as the Head of the Department of Neuropathology at Royal Prince Alfred Hospital . He is the founder of the Australian Sports Brain Bank and co-director of the Multiple Sclerosis Australia Brain Bank , with leadership roles in the Brain & Mind Centre and Brainstorm initiatives. His research focuses on Chronic Traumatic Encephalopathy , Gliomas , Epigenetics , and Neuroinflammatory diseases , with a strong emphasis on Neurodegenerative diseases and Molecular neuropathology . He employs Genetics , Pathology , and Translational Research to bridge clinical and molecular insights. Recent publications highlight work on immune checkpoint therapies for glioblastoma, neurotoxic elements in multiple sclerosis, and epitranscriptomic biomarkers for brain tumors. His collaborative studies span neuro-oncology , traumatic brain injury , and AI-driven pathology innovations. No scientific awards or student advisement details were explicitly mentioned.

• Cancer Cell Biology
• Disease Modelling
• Stem Cells
• +۱ مورد دیگر

Christopher Mapperley is a Postdoctoral Researcher specializing in the regulation of haematopoiesis by the epitranscriptome, with a focus on both normal and malignant processes. He is supervised by Professor Kamil R. Kranc and affiliated with the Centre for Haemato-Oncology. His research intersects critical areas in biomedical science, including cancer biology and stem cell dynamics. Research Interests: Cancer Cell Biology Disease Modelling Stem Cells Leukaemia As a postdoctoral researcher, Mapperley contributes to advancing knowledge in haemato-oncology through molecular and cellular investigations. No additional information about publications, awards, or formal affiliations beyond the Centre for Haemato-Oncology is provided in the available text.

• Genomics
• Bioinformatics
• Haematopoiesis
• +۵ مورد دیگر

Louie Van de Lagemaat is a bioinformatician at the University of Aberdeen's Centre for Genome-Enabled Biology and Medicine (School of Medicine, Medical Sciences and Nutrition), joining in October 2021. He holds a PhD in Genetics from the University of British Columbia (2006) and has extensive experience in genomic data analysis. Research Interests : Haematopoiesis, molecular neuroscience, and transcriptomics using high-throughput sequencing technologies. Expertise : ChIP-seq, RNA-seq, Ribo-seq, and meRIP-seq analysis, with a focus on HLA allele heterozygosity and epigenetic regulation. Collaborations : Active in interdisciplinary studies with researchers in stem cell biology, cancer genomics, and neurogenetics.

Mati Karelsonمشاهده پروفایل

استاد

• Computational Chemistry
• QSAR Modeling
• Drug Design
• +۵ مورد دیگر

Mati Karelson is a Full Professor at the University of Tartu's Institute of Chemistry in Estonia, where he has maintained a continuous academic appointment since September 1992. With an educational background in Chemistry from Tartu State University (1992-1995), he has established himself as a leading researcher in computational chemistry and drug design. Professor Karelson's research spans multiple disciplines with a strong focus on computational approaches to drug discovery . His work prominently features: Quantitative Structure-Activity Relationship (QSAR) modeling Molecular docking and virtual screening Epitranscriptomics, particularly RNA methylation (m6A) Neurodegenerative disease research, especially Parkinson's disease Antiviral drug development targeting HIV and flaviviruses His recent publications (2023-2025) demonstrate a strong emphasis on the intersection of computational chemistry and biological applications, particularly in developing small molecule modulators of RNA methylation pathways and their therapeutic potential for neurological disorders and viral infections. Professor Karelson has published 238 papers with over 44,875 reads and 13,947 citations, reflecting significant impact in his field. His research collaborations span multiple institutions internationally, working with experimental biologists to validate computational predictions. The interdisciplinary nature of his work bridges computational chemistry with neuroscience, virology, and molecular biology, creating a robust research program with translational potential.

Robert Schneiderمشاهده پروفایل

استاد

• Epigenetics
• Chromatin Biology
• Metabolism-Epigenetics Crosstalk
• +۴ مورد دیگر

Prof. Robert Schneider serves as Professor at Ludwig-Maximilians-Universität München's Faculty of Biology and Director of the Institute of Functional Epigenetics at Helmholtz Zentrum München. He leads Project A20 within the Collaborative Research Center 1064, investigating how metabolic enzymes and their products regulate chromatin dynamics and gene expression. His dual appointments position him at the nexus of academic research and translational biomedical science in Munich's vibrant research ecosystem. His academic journey began with Biology Diploma studies (1990-1996) and doctoral research (1996) at LMU Munich under Prof. Regine Kahmann. This was followed by an EMBO fellowship at Cambridge's Gurdon Institute (2000-2004), a Max Planck Research Group leadership in Freiburg (2005-2012), and Director de Recherche position at Strasbourg's IGBMC (2012-2016) before his current roles. Research focuses on metabolite-chromatin crosstalk, particularly how short-chain acyl-CoAs drive histone lysine acylations to reprogram gene expression. The lab employs innovative approaches including metabolic enzyme recruitment to specific genes, in vitro chromatin reconstitutions, and single-cell tracing of transcriptional memory. Current work emphasizes RNA modification enzymes (e.g., METTL5/6) in pluripotency and the role of sugar metabolism in epigenetic inheritance. This research provides fundamental insights into how nutrition and metabolism shape genomic regulation with implications for cancer and developmental disorders. Recent publications (2017-2020) reveal a strategic expansion from histone modifications into RNA epigenetics and single-cell dynamics of metabolic-epigenetic interactions. The work consistently bridges biochemical mechanism with functional outcomes in stem cells and disease models, demonstrating increasing technical sophistication through integrative genomics and live-cell imaging approaches. Major recognitions include: ERC Starting Grant (2008) HFSP Career Development Award (2006) Chaire Gutenberg, University of Strasbourg (2012) Multiple labellisation awards from French research foundations (2012-2014) Epigenome Network of Excellence membership Mentorship occurs through structured PhD programs including CRC 1064's graduate initiatives and Helmholtz's doctoral training. The lab maintains active grants from DFG (CRC 1064), ERC, and collaborative consortia, supporting interdisciplinary projects that attract international talent. Prof. Schneider serves on editorial boards (PLOS Genetics) and selection committees, fostering global scientific exchange while maintaining a highly collaborative lab environment focused on mechanistic epigenetics. The Institute of Functional Epigenetics operates as a dynamic hub within Helmholtz Zentrum München, combining biochemical expertise with genomic and computational approaches. The lab's integration into CRC 1064 enables synergistic collaborations across Munich's research institutions, particularly in developing novel methods to probe metabolism-chromatin interfaces in real time.

Benayahu Elbaz-eilonمشاهده پروفایل

استادیار

• Myelin Biology
• Neuroimmunology
• Multiple Sclerosis
• +۵ مورد دیگر

Dr. Benayahu Elbaz-eilon serves as an Assistant Professor in the Department of Neurology at Northwestern University's Feinberg School of Medicine, specializing in the MS/Neuroimmunology division. His research program focuses on the molecular mechanisms regulating myelin-forming cells in both central and peripheral nervous systems. BS: Bar-Ilan University (2002) MS: Bar-Ilan University (2004) PhD: The Hebrew University of Jerusalem (2010) Postdoctoral Training: University of Chicago, Neuroscience (2016) Dr. Elbaz-eilon's research centers on transcriptional control of oligodendrocyte differentiation and CNS myelination, with particular emphasis on the ZFP24 transcription factor. His laboratory investigates how oligodendrocyte lineage cells shape the brain's extracellular matrix and explores metabolic pathways protecting against lipid peroxidation. In the peripheral nervous system, his team studies injury mechanisms, recovery processes, and remyelination following damage to Schwann cells. His work bridges fundamental developmental neurobiology with translational applications for demyelinating disorders like multiple sclerosis. Analysis of Dr. Elbaz-eilon's publication record reveals a consistent research trajectory focused on myelin biology, with recent work (2020-2024) increasingly emphasizing transcriptional regulation in oligodendrocytes, neuron-glia interactions, and the molecular basis of demyelinating diseases. His publications span high-impact journals including Neuron, Cell Reports, and Nature Nanotechnology, demonstrating interdisciplinary approaches combining molecular neuroscience with advanced bioengineering techniques. Dr. Elbaz-eilon leads an active research laboratory with current staff including Research Technologists Haley Tokars and Tanya Klein. His laboratory is part of Northwestern's Neuroimmunology Research program, collaborating with the Popko Lab and other neuroscience research groups within the Feinberg School of Medicine. He serves on the Editorial Board of Frontiers in Cellular Neuroscience (2023-present) and is a member of the American Society for Neurochemistry (2022-present).